

October 31, 2026

To,
The BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip Code: 540737

Dear Sir/Ma'am,

Sub: Outcome of the Board Meeting held today i.e. Saturday, October 31, 2026.

With reference to the captioned subject matter, we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Saturday, October 31, 2026 has inter alia considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended on September 30, 2026, along with the Limited Review Reports of Auditors thereon pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"). The copy of the said financial results along with the Limited Review Reports of the Auditors are enclosed herewith.

The Meeting of the Board of Directors of the Company commenced at 04:30 p.m. and concluded at 05:00 p.m.

Kindly take the same on your record.

Thanking you,

Yours Faithfully,

For Shree Ganesh Remedies Limited

AKANKSHA

Digitally signed by
AKANKSHA
Date: 2026.10.31 17:45:16
+05'30'

Akanksha
Company Secretary and Compliance Officer



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. : L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2, -6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1ZQ (Zero)



www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com | **E MAIL**



Independent Auditor's Review Report on Unaudited Quarterly Standalone Financial Results of Shree Ganesh Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors,
Shree Ganesh Remedies Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Shree Ganesh Remedies Limited** ("the Company") for the quarter ended September 30th, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Mail : office@cachaudharyshah.com
Website : www.cachaudharyshah.com
Phone : +91 79 - 4890 4596
Mobile : +91 93774 71779
 : +91 94616 36460
 : +91 97692 99002

Head Office : 406, Central Business Space, Opp. Sukhsagar Complex, Usmanpura, Ahmedabad, Gujarat - 380 013.
Branch Office : B-102, Panchratna Chs, Opp. Dainik Chinese Corner, Thane West, Mumbai, Maharashtra, - 400 601.
Other Branches : Bengaluru (Karnataka) | Kolhapur (Maharashtra) | Jaipur (Rajasthan) | London (United Kingdom)



CHAUDHARY SHAH & ASSOCIATES LLP

LLPN : AAZ-5550

CHARTERED ACCOUNTANTS

Ahmedabad | Mumbai | Bengaluru | Kolhapur | Jaipur | London (UK)

For, Chaudhary Shah & Associates LLP

Chartered Accountants

FRN: 006212C/W100789


31-10-2026



Shubham Jain

Designated Partner

M.No. 474949

UDIN: 26474949BQQIYU8624

Place: Ahmedabad

Date: 31.10.2026

INDIA

Mail : office@cachaudharyshah.com
Website : www.cachaudharyshah.com
Phone : +91 79 - 4890 4596
Mobile : +91 93774 71779
 : +91 94616 36460
 : +91 97692 99002

Head Office : 406, Central Business Space, Opp. Sukhsagar
Complex, Usmanpura, Ahmedabad, Gujarat - 380 013.
Branch Office : B-102, Panchratna Chs, Opp. Dainik Chinese Corner,
Thane West, Mumbai, Maharashtra, - 400 601.
Other Branches : Bengaluru (Karnataka) | Kolhapur (Maharashtra) |
Jaipur (Rajasthan) | London (United Kingdom)

Independent Auditor's Review Report on Unaudited Quarterly Consolidated Financial Results of Shree Ganesh Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors,
Shree Ganesh Remedies Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Shree Ganesh Remedies Limited ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended September 30, 2026 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entity:

Name of the Entity	Relationship
SGRL USA INC	Wholly Owned Subsidiary [with effect from January 8, 2024]



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matters

6. The accompanying Statement includes the unaudited interim financial results/financial information of 1 (one) subsidiary located outside India, whose unaudited interim financial results/financial information reflect total revenue of ₹ NIL lakhs, total net profit/ (loss) after tax (including due to exchange translation) of ₹ (0.47) lakhs and total comprehensive income/(loss) (including due to exchange translation) of ₹ (0.04) lakhs, for the quarter ended September 30th, 2026 as considered in the Statement. The management of the Holding Company has prepared and certified the unaudited interim financial results/ financial information of this 1 (one) subsidiary in accordance with Ind AS and accounting principles generally accepted in India, and our opinion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary, is based solely on such financial results/ financial information. In our opinion and according to the information and explanation given to us by the management of the Holding Company, this unaudited interim financial results/ financial information is not material to the Group.

For, Chaudhary Shah & Associates LLP**Chartered Accountants****FRN: 006212C/W100789**
31-10-2026**Shubham Jain****Designated Partner****M.No. 474949****UDIN: 26474949XKPHMF9441****Place: Ahmedabad****Date: 31.10.2026**

Balance Sheet As at September 30, 2026

₹ in Lakhs

Particulars	Standalone		Consolidation	
	As at September 30, 2026	As at March 31, 2026	As at September 30, 2026	As at March 31, 2026
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
ASSETS				
1. Non-current Assets				
(a) Property, Plant and Equipment	6,462.99	6,808.44	6,462.99	6,808.44
(b) Capital Work-in-progress	1,630.06	1,237.81	1,630.06	1,237.81
(c) Right-of-use Assets	3,629.02	3,654.51	3,629.02	3,654.51
(d) Other Intangible Assets	2.33	2.75	2.33	2.75
(e) Intangible Assets under development	59.40	48.54	59.40	48.54
(f) Financial Assets				
(i) Investments	16.30	16.30	8.00	8.00
(ii) Other Financial Assets	227.19	242.99	227.19	242.99
(g) Other Non-current Assets	258.13	179.44	258.13	179.44
Total Non-current Assets	12,285.42	12,190.78	12,277.12	12,182.48
2. Current Assets				
(a) Inventories	3,352.92	2,400.52	3,352.92	2,400.52
(b) Financial Assets				
(i) Investments	1,137.80	1,245.39	1,137.80	1,245.39
(ii) Trade Receivables	2,112.13	3,256.50	2,112.13	3,256.50
(iii) Cash and Cash Equivalents	1,727.74	1,335.90	1,730.92	1,339.52
(iv) Bank Balances other than (iii) of above	8.63	8.73	8.63	8.73
(v) Other Financial Assets	27.10	17.56	27.10	17.56
(c) Other Current Assets	354.14	318.24	354.14	318.24
(d) Current Tax Assets (Net)	31.60	-	31.60	-
Total Current Assets	8,752.06	8,582.84	8,755.24	8,586.46
Total Assets	21,037.48	20,773.62	21,032.36	20,768.94
EQUITY AND LIABILITIES				
1. Equity				
(a) Equity Share Capital	1,283.76	1,283.76	1,283.76	1,283.76
(b) Other Equity	15,295.72	15,017.78	15,290.61	15,013.10
Total Equity	16,579.48	16,301.54	16,574.37	16,296.86
2. Liabilities				
(A) Non-current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	2,062.09	2,124.77	2,062.09	2,124.77
(ii) Lease Liabilities	14.90	12.73	14.90	12.73
(b) Provisions	62.41	57.39	62.41	57.39
(c) Deferred Tax Liabilities (Net)	121.13	107.98	121.13	107.98
Total Non-current Liabilities	2,260.53	2,302.87	2,260.53	2,302.87
(B) Current Liabilities				
(a) Financial Liabilities				
(i) Borrowings	536.90	942.45	536.90	942.45
(ii) Lease Liabilities	-	1.34	-	1.34
(iii) Trade Payables				
(a) Total outstanding dues of micro and small enterprises	183.63	85.94	183.62	85.94
(b) Total outstanding other than (ii) (a) above	1,300.41	858.23	1,300.41	858.23
(iv) Other Financial Liabilities	147.65	200.38	147.65	200.38
(b) Provisions	3.56	3.51	3.56	3.51
(c) Current Tax Liabilities (Net)	-	55.59	-	55.59
(d) Other Current Liabilities	25.32	21.77	25.32	21.77
Total Current Liabilities	2,197.47	2,169.71	2,197.46	2,169.21
Total Liabilities	4,458.00	4,472.08	4,457.99	4,472.08
TOTAL EQUITY AND LIABILITIES	21,037.48	20,773.62	21,032.36	20,768.94

For Shree Ganesh Remedies Ltd.

Chandulal Manubhai Kothia
DIN: 00652806
Managing Director
Place: Ankleshwar
Date: 31/10/2026



For Chaudhary Shah and Associates LLP
Chartered Accountants, FRN:006212C/A/100789

31-10-2026
Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad, Date: 31/10/2026



Head Office :

Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
PIN No - 393002

(Unit-2) :

Plot No. 6714/2, -6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1Z0 (Zero)



www.ganeshremedies.com
WEBSITE

contact@ganeshremedies.com

EMAIL

Shree Ganesh Remedies Limited
CIN:L24230GJ1995PLC025661
Standalone Financial Results For the Half Year Ended September 30, 2026

₹ in Lakhs

Sr. No.	Particular	Quarter ended			Half Year Ended		Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	INCOME						
I	Revenue from Operations	2,329.47	1,436.00	3,031.50	3,765.47	5,498.29	10,928.58
II	Other Income	140.60	93.92	68.98	234.52	135.16	303.02
III	Total Income (I + II)	2,470.07	1,529.92	3,100.49	3,999.99	5,633.44	11,231.60
	EXPENSES						
IV	Cost of Materials Consumed	1,379.81	839.64	1,219.84	2,219.45	2,093.89	4,091.90
	Changes in inventories of Finished Goods, Stock-in-trade and Work-in-progress	(429.53)	(630.96)	39.32	(1,060.49)	38.05	95.69
	Employee Benefit Expenses	313.28	292.90	296.74	606.18	566.56	1,140.04
	Finance Costs	57.53	31.89	101.01	89.42	195.03	356.19
	Depreciation and Amortisation expense	250.34	244.11	258.74	494.45	500.75	1,047.30
	Other Expenses	672.29	599.22	513.73	1,271.51	1,108.26	2,098.99
	Total Expenses (IV)	2,243.72	1,376.80	2,429.37	3,620.52	4,502.53	8,830.11
V	Profit/(Loss) before Tax (III-IV)	226.35	153.12	671.11	379.47	1,130.91	2,401.49
VI	Tax Expense						
	Current Tax	57.10	34.58	153.80	91.68	255.68	564.83
	Deferred Tax	5.79	6.53	21.74	12.32	34.73	53.31
	(Excess)/Short provision of tax of earlier years	-	-	-	-	-	6.02
	Total Tax Expense (VI)	62.89	41.11	175.54	104.00	290.41	624.16
VII	Profit/(Loss) for the period after Tax (V-VI)	163.46	112.01	495.57	275.47	840.51	1,777.33
VIII	OTHER COMPREHENSIVE INCOME						
	Items that will not be reclassified to profit or loss						
	Exchange Differences in translating the financial statements of foreign operations						-
	Remeasurement Gain/ (Loss) on Defined Measurement Benefit Plans	1.64	1.65	(3.87)	3.29	(4.31)	6.60
	Income Tax Relating to above	(0.41)	(0.42)	0.97	(0.83)	1.09	(1.66)
	Total Other Comprehensive Income for the period (VIII)	1.23	1.23	(2.90)	2.46	(3.22)	4.95
IX	Total Comprehensive Income for the period (VII+VIII)	164.69	113.24	492.67	277.93	837.29	1,782.27
X	Earning Per Share of ₹ 10 Par Value						
	Paid - up Equity Share Capital (Face Value ₹ 10 each)	1,283.76	1,283.76	1,283.76	1,283.76	1,283.76	1,283.76
	Basic (In ₹ per share)	1.28	0.87	3.86	2.15	6.55	13.84
	Diluted (In ₹ per share)	1.28	0.87	3.86	2.15	6.55	13.84

For Shree Ganesh Remedies Ltd.

Chaudhary Manish Kishor
DIN: 00652805
Managing Director

Place: Ankleshwar
Date: 31/10/2026



For Chaudhary Shah and Associates LLP
Chartered Accountants, FRN:006212C/W100789

Shubham Jain
31-10-2026

Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad, Date: 31/10/2026



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. : L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2, -6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1Z0 (Zero)



www.ganeshremedies.com
WEBSITE

contact@ganeshremedies.com

E MAIL

Shree Ganesh Remedies Limited
CIN:L24230GJ1995PLC025661
Consolidated Financial Results For the Half Year Ended September 30, 2026

Sr. No.	Particular	Quarter ended			Half Year Ended		Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	INCOME						
I	Revenue from Operations	2,329.47	1,436.00	3,031.50	3,765.47	5,498.29	10,928.58
II	Other Income	140.60	93.92	68.96	234.52	135.16	303.02
III	Total Income (I + II)	2,470.07	1,529.92	3,100.49	3,999.99	5,633.44	11,231.60
	EXPENSES						
IV	Cost of Materials Consumed	1,379.81	839.64	1,219.84	2,219.45	2,093.89	4,091.90
	Changes in inventories of Finished Goods, Stock-in-trade and Work-in-progress	-429.53	(630.96)	39.32	(1,060.49)	38.05	95.69
	Employee Benefit Expenses	313.28	292.90	296.74	606.18	566.56	1,140.04
	Finance Costs	57.53	31.89	101.01	89.42	195.03	356.19
	Depreciation and Amortisation expense	250.34	244.11	258.74	494.45	500.75	1,047.30
	Other Expenses	672.29	599.22	513.73	1,271.51	1,108.26	2,098.99
	Total Expenses (IV)	2,243.72	1,376.80	2,429.37	3,620.52	4,502.53	8,830.11
V	Profit/(Loss) before Tax (III-IV)	226.35	153.12	671.11	379.47	1,130.91	2,401.49
VI	Tax Expense						
	Current Tax	57.57	34.58	153.80	92.15	256.11	566.17
	Deferred Tax	5.79	6.53	21.74	12.32	34.73	53.31
	(Excess)/Short provision of tax of earlier years	-	-	-	-	-	6.02
	Total Tax Expense (VI)	63.36	41.11	175.54	104.47	290.84	625.50
VII	Profit/(Loss) for the period after Tax (V-VI)	162.99	112.01	495.57	275.00	840.08	1,775.99
VIII	OTHER COMPREHENSIVE INCOME						
	Items that will not be reclassified to profit or loss						
	Exchange Differences in translating the financial statements of foreign operations	0.05	(0.01)	0.15	0.04	0.13	0.36
	Remeasurement Gain/(Loss) on Defined Measurement Benefit Plans	1.64	1.65	(8.87)	3.29	(4.31)	6.40
	Income Tax Relating to above	-0.42	(0.41)	0.97	(0.83)	1.09	(1.66)
	Total Other Comprehensive Income for the period (VIII)	1.27	1.23	(1.75)	2.50	(3.09)	5.30
IX	Total Comprehensive Income for the period (VII+VIII)	164.26	113.24	493.82	277.50	836.98	1,781.29
X	Earning Per Share of ₹ 10 Par Value						
	Paid-up Equity Share Capital (Face Value: ₹ 10 each)	1,283.76	1,283.76	1,283.76	1,283.76	1,283.76	1,283.76
	Basic (in ₹ per share)	1.27	0.87	3.86	2.14	6.54	13.83
	Diluted (in ₹ per share)	1.27	0.87	3.86	2.14	6.54	13.83

For Shree Ganesh Remedies Ltd.


Chandulal Manubhai Kothia
DIN: 00652806
Managing Director

Place: Ankleshwar
Date: 31/10/2026



For Chaudhary Shah and Associates LLP
Chartered Accountants, FRN:006212C/W100789


Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad, Date: 31/10/2026



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. - I 24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2, -6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1ZD (Zero)



www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com
EMAIL

Statement of Cash Flows For the Half Year Ended September 30, 2026

₹ in Lakhs

Particulars	Standalone		Consolidation	
	Half Year Ended on September 30, 2026 (Unaudited)	Half Year Ended on September 30, 2025 (Unaudited)	Half Year Ended on September 30, 2026 (Unaudited)	Half Year Ended on September 30, 2025 (Unaudited)
Cash Flow from Operating Activities				
Profit Before Tax	379.47	1,130.91	379.47	1,130.91
Adjustments for:				
Depreciation and Amortisation	494.45	500.75	494.45	500.75
Interest Income	(0.38)	(14.83)	(0.38)	(14.83)
Finance Cost	89.42	195.03	89.42	195.03
(Gain)/Loss on Sale of Current Investments	(38.11)	(21.65)	(38.11)	(21.65)
Unrealized Foreign Exchange Loss/(Gain) (Net)	-	105.45	0.04	105.58
Fair value Gain on Current Investments	7.93	(29.55)	7.93	-29.55
Fair Valuation of Derivative Contracts	-	(24.14)	-	-24.14
Remeasurement of the defined benefit Plans	3.29	(4.31)	3.29	(4.31)
Non-cash income or exps				
Changes in Working Capital				
(Increase) / Decrease in Other Non Current Financial Assets	15.60	(83.47)	15.60	(83.47)
Decrease / (Increase) in Inventories	(952.40)	(11.95)	(952.40)	(11.95)
(Increase) / Decrease in Trade Receivables	1,144.37	(167.23)	1,144.37	(167.23)
(Increase) / Decrease in Other Current Assets	(32.39)	126.25	(32.39)	126.25
Increase/ (Decrease) in Other Current liabilities	3.55	4.96	3.55	4.96
Increase/ (Decrease) in Trade Payables	539.86	352.92	539.86	352.92
Increase/ (Decrease) in Other Current Financial liabilities	(17.16)	12.92	(17.16)	12.92
(Decrease)/ Increase in Provisions	5.07	15.52	5.07	15.52
Income Taxes (Paid) / Refund received	(178.86)	(322.10)	(179.34)	(322.10)
Net Cash Generated / (Used) from Operating Activities (A)	1,463.71	1,765.90	1,463.27	1,765.61
Cash Flow from Investing Activities				
Investment in Mutual Fund (Net of Proceeds on sale)	137.77	212.01	137.77	212.01
Investments in Subsidiary	-	(208.99)	-	-208.99
Sale of Property, Plant and Equipment	0.22	-	0.22	Nil
Acquisition of Property Plant and Equipment	(642.43)	(637.77)	(642.43)	(837.77)
Interest Income	(12.67)	14.47	(12.67)	14.47
Fixed Deposits Matured / (Placed) (Net)	0.30	(3.02)	0.30	(3.02)
Net Cash Generated / (Used) from Investing Activities (B)	(516.81)	(823.30)	(516.81)	(823.30)
Cash Flow from Financing Activities				
Issue of Shares under Rights Issue (Net of Expenses)	-	-	-	-
Finance Costs	(86.85)	(197.65)	(86.85)	(197.65)
Proceeds from / (Repayment of) Secured Loans (Net)	(467.48)	(373.79)	(467.48)	(373.79)
Proceeds from / (Repayment of) Unsecured Loans (Net)	(0.73)	(1.18)	(0.73)	(1.17)
Payment of Lease Liabilities	-	-	-	-
Net Cash Generated / (Used) from Financing Activities (C)	(555.06)	(572.62)	(555.06)	(572.61)
Net increase / decrease in cash and cash equivalents (A+B+C)	391.84	369.96	391.40	369.70
Cash and Cash equivalents at the beginning of the period	1,335.90	990.10	1,339.52	994.66
Less: Effect of Exchange gain/(loss) on Cash and Cash Equivalents	-	122.15	-	122.15
Cash and Cash Equivalents at the end of the period	1,727.74	1,482.23	1,730.92	1,486.51

Particulars	Half Year Ended on September 30, 2026 (Unaudited)	Half Year Ended on September 30, 2025 (Unaudited)	Half Year Ended on September 30, 2026 (Unaudited)	Half Year Ended on September 30, 2025 (Unaudited)
Cash and Cash Equivalents comprises of :				
Balance with bank				
- In Current Account	1,727.36	1,482.00	1,730.54	1,486.28
- Working capital facility from bank	-	-	-	-
Cash on hand	0.38	0.23	0.38	0.23
Total	1,727.74	1,482.23	1,730.92	1,486.51

For Shree Ganesh Remedies Ltd.

For Chaudhary Shah and Associates LLP

Chartered Accountants, FRN:006212C/W100789

Chandulal Manubhai Kothia
DIN: 00652806
Managing Director
Place: Ankleshwar
Date: 31/10/2026



31-10-2026

Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad, Date: 31/10/2026



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. U24230G11905PL0295661

(Unit-2) :
Plot No. 6714/2, 6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1Z0 (Zero)



www.ganeshremedies.com
WEBSITE

contact@ganeshremedies.com

E MAIL

Shree Ganesh Remedies Limited

CIN:L24230GJ1995PLC025661

Notes to Financial Results for the Half Year Ended September 30, 2025

- 1 The above results which are published have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on October 31, 2026. The Financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
- 2 The Company is primarily engaged in the business of Bulk Drug Intermediates, which constitute a single reportable segment in accordance with Ind AS 108 - "Segment Reporting".
- 3 Earnings per share (EPS) is calculated on the weighted average of share capital outstanding during the period / year as per Ind AS 33 on "Earnings Per Share". EPS for the Quarter ended September 30, 2026, June 30, 2026, September 30, 2025 and half year ended September 30, 2026, September 30, 2025 are not annualised.
- 4 Kamalam Foundation which is incorporated under Section 8 of the Companies Act, 2013 is prohibited to give any right over their profits to its members and accordingly, no share in surplus of Kamalam Foundation is considered to be that of the Company for the purpose of preparation and presentation of consolidated financial results/financial statements/financial information.
- 5 Previous year's / period's figures are regrouped wherever necessary to make them comparable with current year's / period's grouping

For Shree Ganesh Remedies Ltd.


Chandulal Manubhai Kothia
DIN: 00652806
Managing Director
Place: Ankleshwar
Date: 31/10/2026



For Chaudhary Shah and Associates LLP
Chartered Accountants, FRN:006212C/W100789


31/10/2026
Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad, Date: 31/10/2026



Head Office :
Plot No. 6011, 6012, 6002 & 6003,
GIDC Estate, Ankleshwar - 393 002,
Gujarat (INDIA)

(Unit-2) :
Plot No. 6714/2, -6715 GIDC Estate,
Ankleshwar - 393 002 Gujarat (INDIA)



www.ganeshremedies.com
WEBSITE